title: Comparison of efficacy of cefoperazone/sulbactam and imipenem/cilastatin for treatment of Acinetobacter bacteremia.
abstract: Multiple antibiotic resistance threatens successful treatment of Acinetobacter baumannii infections worldwide. Increasing interest in the well-known activity of sulbactam against the genus Acinetobacter has been aroused. The purpose of this study was to compare the outcomes for patients with Acinetobacter bacteremia treated with cefoperazone/sulbactam versus imipenem/cilastatin. Forty-seven patients with Acinetobacter baumannii bacteremia were analyzed through a retrospective review of their medical records for antibiotic therapy and clinical outcome. Thirty-five patients were treated with cefoperazone/sulbactam, and twelve patients with imipenem/cilastatin. The percentage of favorable response after 72 hours was not statistically different between cefoperazone/sulbactam group and imipenem/cilastatin group. The mortality rate was not statistically different, too. Cefoperazone/sulbactam was found to be as useful as imipenem/cilastatin for treating patients with Acinetobacter bacteremia.
authors.affiliation: Department of Internal Medicine, Yonsei University College of Medicine, Seodaemun-gu, Seoul 120-752, Korea.
authors.forename: Jun Yong
authors.initials: JY
authors.lastname: Choi
authors.forename: Chang Oh
authors.initials: CO
authors.lastname: Kim
authors.forename: Yoon Seon
authors.initials: YS
authors.lastname: Park
authors.forename: Hee Jung
authors.initials: HJ
authors.lastname: Yoon
authors.forename: So Youn
authors.initials: SY
authors.lastname: Shin
authors.forename: Young Keun
authors.initials: YK
authors.lastname: Kim
authors.forename: Myung Soo
authors.initials: MS
authors.lastname: Kim
authors.forename: Yeon-A
authors.initials: YA
authors.lastname: Kim
authors.forename: Young Goo
authors.initials: YG
authors.lastname: Song
authors.forename: Dongeun
authors.initials: D
authors.lastname: Yong
authors.forename: Kyungwon
authors.initials: K
authors.lastname: Lee
authors.forename: June Myung
authors.initials: JM
authors.lastname: Kim
mesh_terms: D000150:Acinetobacter / Q000187:drug effects / Q000302:isolation & purification; D000151:Acinetobacter Infections / Q000188:drug therapy* / Q000401:mortality; D000293:Adolescent; D000328:Adult; D000368:Aged; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D016470:Bacteremia / Q000188:drug therapy*; D002438:Cefoperazone / Q000627:therapeutic use*; D015377:Cilastatin / Q000627:therapeutic use; D024881:Drug Resistance, Bacterial; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D015378:Imipenem / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D011480:Protease Inhibitors / Q000627:therapeutic use; D013407:Sulbactam / Q000627:therapeutic use*
chemical_list: D000900:Anti-Bacterial Agents; D011480:Protease Inhibitors; D015377:Cilastatin; D015378:Imipenem; D002438:Cefoperazone; D013407:Sulbactam